Combination Approaches Help Some Younger Breast Cancer Patients

December 12, 2014 5:24 PM

3 0

Prudence A. Francis, MD, from the University of Melbourne in Australia, and colleagues examined the role of adjuvant ovarian suppression in hormone receptor-positive early breast cancer recurrence. The authors randomized 3,066 premenopausal women, classified according to prior receipt or nonreceipt of chemotherapy, to 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression.

After a median follow-up of 67 months, the researchers found that the estimated five-year disease-free survival was not significantly different between the tamoxifen-ovarian suppression and the tamoxifen groups (86.6 and 84.7%, respectively; hazard ratio, 0.83; 95% confidence interval [CI], 0.66 to ...

Read more

To category page